{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:50:11Z","timestamp":1791010211534,"version":"4.1.0"},"reference-count":35,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer-associated cachexia (CAC) is a debilitating condition marked by muscle and fat loss, that is unresponsive to nutritional support and contributes significantly to morbidity and mortality in patients with cancer. Immune dysfunction, driven by cytokine imbalance, contributes to CAC progression. This review explores the potential relationship between CAC and anti-cancer immune response in pre-clinical and clinical studies. Pre-clinical studies showcase the involvement of cytokines like IL-1\u03b2, IL-6, IL-8, IFN-\u03b3, TNF-\u03b1, and TGF-\u03b2, in CAC. IL-6 and TNF-\u03b1, interacting with muscle and adipose tissues, induce wasting through JAK\/STAT and NF-\u03baB pathways. Myeloid-derived suppressor cells (MDSCs) exacerbate CAC by promoting inflammation. Clinical studies confirm elevated pro-inflammatory cytokines (IL-6, IL-8, TNF\u03b1) and immune markers like the neutrophil-to-lymphocyte ratio (NLR) in patients with CAC. Thus, immunomodulatory mechanisms involved in CAC may impact the anti-neoplastic immune response. Inhibiting CAC mechanisms could enhance anti-cancer therapies, notably immunotherapy. R-ketorolac, a new immunomodulator, reversed the weight loss and increased survival in mice. Combining these agents with immunotherapy may benefit patients with cancer experiencing CAC. Further research is vital to understand the complex interplay between tumor-induced immune dysregulation and CAC during immunotherapy.<\/jats:p>","DOI":"10.3390\/cancers16091709","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T06:13:22Z","timestamp":1714371202000},"page":"1709","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Immune System Disorder and Cancer-Associated Cachexia"],"prefix":"10.3390","volume":"16","author":[{"given":"Lingbing","family":"Zhang","sequence":"first","affiliation":[{"name":"Yinuoke Ltd., Changchun 130012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Bonomi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jare.2023.04.018","article-title":"Immunoregulation in cancer-associated cachexia","volume":"58","author":"Wu","year":"2023","journal-title":"J. Adv. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1517\/14712598.2011.592826","article-title":"Unresolved inflammation:\u2018immune tsunami\u2019or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer","volume":"11","author":"Khatami","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ferrara, M., Samaden, M., Ruggieri, E., and Venereau, E. (2022). Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.960341"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fonc.2020.00298","article-title":"Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options","volume":"10","author":"Marceca","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/mco2.164","article-title":"Targeting cancer cachexia: Molecular mechanisms and clinical study","volume":"3","author":"Wang","year":"2022","journal-title":"MedComm"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lee, Y.H., Tsai, K.W., Lu, K.C., Shih, L.J., and Hu, W.C. (2022). Cancer as a Dysfunctional Immune Disorder: Pro-Tumor TH1-like Immune Response and Anti-Tumor TH\u03b1\u03b2 Immune Response Based on the Complete Updated Framework of Host Immunological Pathways. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102497"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"793234","DOI":"10.3389\/fimmu.2022.793234","article-title":"Autoimmunity and Cancer\u2014Two Sides of the Same Coin","volume":"13","author":"Sakowska","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/jir.2018.0060","article-title":"Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity","volume":"39","author":"Valencia","year":"2019","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12986-019-0409-9","article-title":"Plasma concentration of interleukin-6 was upregulated in cancer cachexia patients and was positively correlated with plasma free fatty acid in female patients","volume":"16","author":"Han","year":"2019","journal-title":"Nutr. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e54095","DOI":"10.7554\/eLife.54095","article-title":"Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer","volume":"9","author":"Burfeind","year":"2020","journal-title":"Elife"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.15252\/emmm.201607052","article-title":"STAT3 promotes IFN\u03b3\/TNF\u03b1-induced muscle wasting in an NF-\u03baB-dependent and IL-6-independent manner","volume":"9","author":"Ma","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jcsm.12441","article-title":"Tumour-derived transforming growth factor-\u03b2 signalling contributes to fibrosis in patients with cancer cachexia","volume":"10","author":"Lima","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cyto.2016.02.015","article-title":"White adipose tissue IFN-\u03b3 expression and signalling along the progression of rodent cancer cachexia","volume":"89","author":"Yamashita","year":"2016","journal-title":"Cytokine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.4049\/jimmunol.181.7.4676","article-title":"A novel role for CD4+ T cells in the control of cachexia","volume":"181","author":"Wang","year":"2008","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/rco2.24","article-title":"JAK Inhibitors Suppress Cancer Cachexia-Associated Anorexia and Adipose Wasting in Mice","volume":"3","author":"Arora","year":"2020","journal-title":"JCSM Rapid Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.21037\/tlcr-21-460","article-title":"Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors: Results from a prospective, observational study","volume":"10","author":"Rounis","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3892\/mco.2022.2524","article-title":"Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer","volume":"16","author":"Fujii","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcp.26811","article-title":"Adipose tissue dysfunction in cancer cachexia","volume":"234","author":"Daas","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.4049\/jimmunol.1302895","article-title":"Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia","volume":"192","author":"Cuenca","year":"2014","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jcsm.12652","article-title":"Inflammation-induced cholestasis in cancer cachexia","volume":"12","author":"Thibaut","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/jcsm.13422","article-title":"R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice","volume":"15","author":"Chrysostomou","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/jcsm.12761","article-title":"Association of systemic inflammation with survival in patients with cancer cachexia: Results from a multicentre cohort study","volume":"12","author":"Zhang","year":"2021","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Alves, M.J., Figueredo, R.G., Azevedo, F.F., Cavallaro, D.A., Neto, N.I., Lima, J.D., Matos-Neto, E., Radloff, K., Riccardi, D.M., and Camargo, R.G. (2017). Adipose tissue fibrosis in human cancer cachexia: The role of TGF\u03b2 pathway. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3178-8"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hou, Y.C., Wang, C.J., Chao, Y.J., Chen, H.Y., Wang, H.C., Tung, H.L., Lin, J.T., and Shan, Y.S. (2018). Elevated Serum Interleukin-8 Level Correlates with Cancer-Related Cachexia and Sarcopenia: An Indicator for Pancreatic Cancer Outcomes. J. Clin. Med., 7.","DOI":"10.3390\/jcm7120502"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"729182","DOI":"10.3389\/fimmu.2021.729182","article-title":"Activation of the Adipose Tissue NLRP3 Inflammasome Pathway in Cancer Cachexia","volume":"12","author":"Murari","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_28","first-page":"247","article-title":"Anti-inflammatory and side effects of cyclo-oxygenase inhibitors","volume":"59","author":"Suleyman","year":"2007","journal-title":"Pharmacol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bonomi, P., Fidler, M.J., Shah, P., and Borgia, J. (2019). Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. Cancers, 11.","DOI":"10.3390\/cancers11111619"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/annonc\/mdw016","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"27","author":"Ferrucci","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1200\/JCO.2005.04.2838","article-title":"Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients","volume":"24","author":"Monk","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jamda.2010.02.012","article-title":"Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia\/cachexia","volume":"12","author":"Chasen","year":"2011","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_35","unstructured":"ClinicalTrial (2024, February 01). A Feasibility Study of Ketorolac Treatment for Cachexia in Patients with Advanced Pancreatic Ductal Adenocarcinoma (KetoROCX), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05336266."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:34:55Z","timestamp":1760106895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/9\/1709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["cancers16091709"],"URL":"https:\/\/doi.org\/10.3390\/cancers16091709","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]}}}